Dimerix Ltd has released a press release.
DMX-200 Dosage Optimisation Study Successfully Completed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Proteomics partnership to improve treatment of CKD
- Entitlement Offer Booklet
- Entitlement Offer to raise $5.5 million
- Suspension from Official Quotation
- Dimerix Phase 2a Subgroup Analysis Results
Later from Dimerix
- Results of Entitlement Offer
- Quarterly Review and Appendix 4C
- Oversubscribed Placement to Raise a Further $4.5m
- Half Year Report and Financial Statements
- CMO Appointment and Clinical Trials Update
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix